Gaiane M. Rauch, M.D., Ph.D.

Peer-Reviewed Articles

1. Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer 143:134-146, 2021. e-Pub 2020. PMID: 33307491.
2. Adrada BE, Moseley T, Kappadath SC, Whitman GJ, Rauch GM. Molecular breast imaging-guided percutaneous biopsy of breast lesions: a new frontier on breast intervention. J Breast Imaging 2(5):484-491, 2020. e-Pub 2020. PMID: 33015619.
3. Ning MS, Venkatesan AM, Stafford RJ, Bui TP, Carlson R, Bailard NS, Vedam S, Davis R, Olivieri ND, Guzman AB, Incalcaterra JR, McKelvey FA, Thaker NG, Rauch GM, Tang C, Frank SJ, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: methods, process workflow, and value-based analysis. Brachytherapy 19(4):427-437, 2020. e-Pub 2019. PMID: 31786169.
4. Kaur H, Ernst RD, Rauch GM, Harisinghani M. Nodal drainage pathways in primary rectal cancer: anatomy of regional and distant nodal spread. Abdom Radiol (NY) 44(11):3527-3535, 2019. e-Pub 2019. PMID: 31628513.
5. Ganeshan D, Nougaret S, Korngold E, Rauch GM, Moreno CC. Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol (NY) 44(11):3709-3725, 2019. e-Pub 2019. PMID: 30953096.
6. Golia Pernicka JS, Sheedy SP, Ernst RD, Minsky BD, Ganeshan D, Rauch GM. MR staging of anal cancer: What the radiologist needs to know. Abdom Radiol (NY) 44(11):3726-3739, 2019. e-Pub 2019. PMID: 31041496.
7. Hope TA, Gollub MJ, Arya S, Bates DDB, Ganeshan D, Harisinghani M, Jhaveri KS, Kassam Z, Kim DH, Korngold E, Lalwani N, Moreno CC, Nougaret S, Paroder V, Paspulati RM, Golia Pernicka JS, Petkovska I, Pickhardt PJ, Rauch GM, Rosenthal MH, Sheedy SP, Horvat N. Rectal cancer lexicon: consensus statement from the Society of Abdominal Radiology rectal & anal cancer disease-focused panel. Abdom Radiol (NY) 44(11):3508-3517, 2019. e-Pub 2019. PMID: 31388697.
8. Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 26(10):3071-3079, 2019. e-Pub 2019. PMID: 31342361.
9. Venkatesan AM, Menias CO, Jones KM, Rauch GM, Stafford RJ, Klopp AH. MRI for radiation therapy planning in human papillomavirus-associated gynecologic cancers. Radiographics 39(5):1476-1500, 2019. e-Pub 2019. PMID: 31498740.
10. Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM. Digital breast tomosynthesis for intraoperative margin assessment during breast-conserving surgery. Ann Surg Oncol 26(6):1720-1728, 2019. e-Pub 2019. PMID: 30877499.
11. Adrada B, Rauch GM. Molecular breast imaging in evaluating breast cancer extent of disease. JBI 1(2):155-156, 2019. e-Pub 2019.
12. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
13. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal carcinoma in situ and margins <2mm: contemporary outcomes with breast conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
14. Tayyab SJ, Adrada BE, Rauch GM, Yang WT. A pictorial review: multimodality imaging of benign and suspicious features of fat necrosis in the breast. Br J Radiol 91(1092):20180213, 2018. e-Pub 2018. PMID: 29987981.
15. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
16. Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol 91(1090):20180300, 2018. e-Pub 2018. PMID: 29947265.
17. Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol 25(7):1953-1960, 2018. e-Pub 2018. PMID: 29667115.
18. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2017. PMID: 28549010.
19. van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg 105(5):535-543, 2018. e-Pub 2018. PMID: 29465744.
20. Adrada BE, Candelaria R, Rauch GM. MRI for the staging and evaluation of response to therapy in breast cancer. Top Magn Reson Imaging 26(5):211-218, 2017. PMID: 28961570.
21. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665-670, 2017. e-Pub 2017. PMID: 28423171.
22. Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-concordant benign MRI-guided vacuum-assisted breast biopsy may not warrant MRI follow-up. AJR Am J Roentgenol 208(4):1-7, 2017. e-Pub 2017. PMID: 28140609.
23. Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, Frumovitz M, Jhingran A, Klopp AH. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 97(3):546-553, 2017. e-Pub 2016. PMID: 28011045.
24. Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol 208(2):1-10, 2017. e-Pub 2016. PMID: 27809573.
25. Parikh AM, Coletta AM, Yu ZH, Rauch GM, Cheung JP, Court LE, Klopp AH. Development and validation of a rapid and robust method to determine visceral adipose tissue volume using computed tomography images. PLoS One 12(8):e0183515, 2017. e-Pub 2017. PMID: 28859115.
26. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS margins and breast conservation: MD Anderson Cancer Center multidisciplinary practice guidelines and outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
27. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of computed tomography- and magnetic resonance imaging-based clinical target volume contours at brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 96(4):793-800, 2016. e-Pub 2016. PMID: 27788952.
28. Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence. Ann Surg Oncol 23(2):482-9, 2016. e-Pub 2015. PMID: 26416712.
29. Swanick CW, Castle KO, Rechner LA, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy 14(3):385-9, 2015. e-Pub 2015. PMID: 25620163.
30. Scoggins ME, Fox PS, Kuerer HM, Rauch GM, Benveniste AP, Park YM, Lari SA, Krishnamurthy S, Yang WT. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol 204(4):878-888, 2015. PMID: 25794082.
31. Adrada BE, Miranda RN, Clemens MW, Rauch GM, Arribas E, Fanale M, Haideri N, Mustafa E, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: analysis of imaging studies in 44 patients reveals need for systematic assessment of mass versus no mass to improve diagnostic accuracy. Plast Reconstr Surg 134(4S-1):95-96, 2014. PMID: 25254804.
32. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 2014. e-Pub 2014. PMID: 25073777.
33. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics 34(4):1082-98, 2014. PMID: 25019443.
34. Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ, Klopp AH. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic dodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88(2):357-62, 2014. PMID: 24411609.
35. Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Clinicopathologic, mammographic, and sonographic features in 1187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139(3):639-647, 2013. e-Pub 2013. PMID: 23774990.
36. Kaur H, Choi H, You YN, Rauch GM, Jensen CT, Hou P, Chang GJ, Skibber JM, Ernst RD. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics 32(2):389-409, 2012. PMID: 22411939.
37. Rauch GM, Dogan BE, Smith TB, Liu P, Yang WT. Outcome analysis of 9-gauge MRI-guided vacuum-assisted core needle breast biopsies. AJR Am J Roentgenol 198(2):292-9, 2012. PMID: 22268171.
38. Meyer JA, Li Y-S, Rauch GM, Haque A. Risk factors for accelerated cerebral degenerative changes and cognitive decline. Research and Practice in Alzheimer's Disease and Other Dementias 5:27-30, 2001.
39. Meyer JS, Thornby J, Li Y-S, Rauch GM. Migraine cluster and chronic daily headaches often accompanied by cognitive decline. John Hopkins University Advanced Studies in Medicine 1:97-100, 2001.
40. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Headache 40(8):638-646, 2000. PMID: 10971660.
41. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 903:411-23, 2000. PMID: 10818532.
42. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment and dementia. Neurobiol Aging 21(2):161-169, 2000.
43. Meyer JS, Rauch GM. Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy. Keio J Med 49 Suppl 1:A25-8, 2000. PMID: 10750330.
44. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. XE-CT CBF changes during normative aging, cognitive decline and dementia. Keio J Med 49 Suppl 1:A95-7, 2000. PMID: 10750350.
45. Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, Terayama Y, Haque A. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 14(12):1050-61, 1999. PMID: 10607973.
46. Mortel KF, Meyer JS, Rauch GM, Konno S, Haque A, Rauch RA. Factors influencing survival among patients with vascular dementia and Alzheimer's disease. J Stroke Cerebrovasc Dis 8(2):57-65, 1999. PMID: 17895141.
47. Konno S, Meyer JS, Margishvili GM, Rauch RA, Haque A. Transformed migraine is a cause of chronic daily headaches. Headache 39(2):95-100, 1999. PMID: 15613201.
48. Meyer JS, Konno S, Margishvili GM, Terayama Y. Vasodilator responses to acetazolamide tested in subtypes of vascular dementia. J Stroke Cerebrovasc Dis 7(5):323-329, 1998. PMID: 17895108.
49. Meyer JS, Terayama Y, Konno S, Margishvili GM, Akiyama H, Rauch RA, Mortel KF, Wills PM. Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia 18:202-208, 1998. PMID: 9642495.
50. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Motel KF. Risk factors for cerebral degenerative changes and dementia. Eur Neurol 39S:7-16, 1998. PMID: 10607973.
51. Konno S, Meyer JS, Terayama Y, Margishvili GM, Mortel KF. Classification, diagnosis and treatment of vascular dementia. Drugs Aging 11:361-373, 1997. PMID: 9359023.
52. Meyer JS, Akiyama H, Konno S, Mortel KF, Margishvili GM. Human aging: risk factors for cerebral atrophy. Ann N Y Acad Sci 826:483-489, 1997. PMID: 9329729.
53. Amcheslavski VG, Demchuk ML, Madorski SV, Toma GI, Margishvili GM, Fokin SV, Savin IA. The use of the preparation of Nimotop in neurosurgical patients. Zh Vopr Neirkhir Im N N Burdenko 3:41-43, 1997. PMID: 9424955.
54. Grindel OM, Koptelov YM, Masherov YL, Voronina IA, Margishvili GM. EEG pathological zone localization in patients with brain tumors by BRAINLOC method. Zhurnal Physiologia cheloveka (Journal of Human Physiology) 23:36-45, 1997.
55. Boldyreva GN, Bragina NN, Margishvili GM, Masherov EL. Effect of a stationary focus of excitation in the limbic structures on spatial-temporal organization of the human EEG. Fiziol Cheloveka 21:18-28, 1995. PMID: http://www.ergopoint.com/mdanderson/login.do;jsessionid=B11A73481A50C7046A2AF3AEC940661F.
56. Livshits AV, Sokolova AA, Margishvili GM. The dynamic changes in the somatosensory evoked potentials in injury of the spinal and spinal cord trauma after meningomyeloradiculolysis. Zh Vopr Neirokhir Im N N Burdenko 1:26-30, 1995. PMID: 7762313.
57. Livshits AV, Sokolova AA, Margishvili GM. Dynamics of somatosensory evoked potentials in patients with spinal tumors. Zhurnal Voprosi Neirochirurgii imeni (Journal Questions of Neurosurgery) 4-5:19-21, 1992.
58. Livshits AV, Sokolova AA, Margishvili MG. [The dynamics of somatosensory evoked potentials in patients with a spinal cord tumor]. Zh Vopr Neirokhir Im N N Burdenko(4-5):19-21, 1992. PMID: 1334307.
59. Candelaria RP, Huang ML, Adrada BE, Santiago L, Basset R, Arribas EM, Scoggins ME, Kuerer HM, Dryden MJ, Le-Petross H, Rauch GM, Yang WT. Diagnostic impact of adding digital breast tomosynthesis alone or with whole-breast ultrasound to full-field digital mammography for local staging of breast cancer: a prospective comparison. Clin Breast Cancer.
60. Yam C, Raghavendra AS, Ding Q, Hess KR, Adrada BE, Candelaria RP, Gould R, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang WT. Impact of sequential biopsies in patients with triple-negative breast cancer receiving neoadjuvant systemic therapy. Clin Cancer Res.
61. Bragg A, Whitman GJ, Candelaria RP, Santiago L, Huang ML, Scoggins ME, Adrada BE, Rauch GM, Wu Y. Imaging of noncalcified DCIS. JBI.
62. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. e-Pub 2020. PMID: 32920733.
63. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol 130:109170. e-Pub 2020. PMID: 32777736.
64. Rauch G, Ueno N, Le-Petross HC. Inflammatory breast cancer. RSNA Case Collection. e-Pub 2020.
65. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging. e-Pub 2021. PMID: 33586845.
66. Chang G, Konishi T, Rauch GM, Kang HC, Gabriel H, Kaur H. MRI staging in an evolving management paradigm for rectal cancer. AJR.
67. Kuerer HM, Gibbons C, Rauch GM, Smith B, Valero V, MacNeill F, Weber W, Rauch G, Heil J, Golatta M, Kolbel V. De-escalation of surgical therapy: What does the data support?. EJC.
68. Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg 155(12):e204103. e-Pub 2020. PMID: 33026457.

Invited Articles

1. Rauch GM, Adrada BE. Comparison of breast MR imaging with molecular breast imaging in breast cancer screening, diagnosis, staging, and treatment response evaluation. Magn Reson Imaging Clin N Am 26(2):273-280, 2018. PMID: 29622132.
2. Adrada BE, Moseley T, Rauch GM. Molecular breast imaging: role as a screening modality. Curr Breast Cancer Rep 8(4):230-235, 2016. e-Pub 2016.

Manuals, Teaching Aids, Other Teaching Publications

1. Sivucha TA, Kochetova AP, Demin VA, Kossichkin MM, Gilinskaia MI, Rauch GM, Olesik I, Liaschevko VI, Volkov AV. Medical and social rehabilitation of the disabled with benign spinal cord tumors: Moscow, 1992.
2. Sivucha TA, Grinchuk VI, Kossichkin MM, Demin VA, Gilinskaia MI, Gendlina IS, Manukian EA, Oleski I, Rauch GM, Smanov KD, Prianikov IV, Malkumiantz TA, Vershinina AB, Polunina LV, Shpirt EI, Drobashenko TG, Petrova OP. Medical and social rehabilitation of the disabled with compromised cerebral venous circulation: Moscow, 1991.

Other Articles

1. Meyer JS, Margishvili GM, Rauch RA, Haque A Late-life migrainous accompaniments. Neurobase, 1998.
2. Meyer JS, Margishvili GM, Rauch RA, Haque A Migrainous infarction. Neurobase, 1998.
3. Meyer JS, Margishvili GM, Konno S Headache associated with metabolic disorders. Neurobase, 1998.
4. Meyer JS, Margishvili GM, Terayama Y, Konno S Headache associated with arterial hypertension. Neurobase, 1997.
5. Tutt B New breast imaging modalities show promise for cancer screening and staging. OncoLog 60(6).

Editorials

1. Pfob A, Sidney-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment. Eur J Cancer 143:178-179, 2021.
2. Rauch GM. ASO Author Reflections: Elimination of breast cancer surgery in complete responders after neoadjuvant chemotherapy: imaging perspective. Ann Surg Oncol 25(Suppl 3):628-629, 2018. PMID: 30244417.
3. Meyer JS, Rauch GM. Gender differences in cerebral perfusion. J Neurol Sci 162(2):113, 1999.

Abstracts

1. Vasaikar S, Seth S, Hollander PD, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Damodaran S, White J, Tripathi D, Piwnica-Worms H, Symmans WF, Chang J, Mani S, Moulder SL. Assessment of mid-neoadjuvant chemotherapy (NACT) biopsies identifies two potential gene signatures that predict for 2 year recurrence free survival (RFS-2) in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium - Virtual, 2020.
2. Candelaria RP, Adrada BE, Lane DL, Bassett R, Santiago L, Rauch GM, Moseley T, Scoggins M, Thompson A, Ravenberg E, White J, Spak D, Le-Petross HC, Arribas E, Whitman G, Leung JT, Litton J, Mittendorf E, Huo L, Valero V, Moulder S, Yang WT. BI-RADS ultrasound lexicon descriptors and tumor-infiltrating lymphocytes in triple negative breast cancer. Virtual - Radiological Society of North America Annual Meeting, 2020.
3. Musall B, Abdelhafez AH, Adrada BE, Jon J, Candelaria RP, Sun J, Yang WT, Santiago L, Whitman G, Le-Petross HC, Moseley T, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Mahmoud H, White J, Hwang KP, Elshafeey N, Mohamed R, Boge M, Kotrotsou A, Zhang S, Damodaran S, Litton J, Valero V, Tripathy D, Thompson A, Wei P, Moulder S, Pagel M, Ma J, Rauch GM. Radiomic features of quantitative apparent diffusion coefficient (ADC) maps from peritumoral regions (PTRs) as predictors of early treatment response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
4. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed R, Yang WT, Elshafeey N, Sun J, Abdelhafez A, Son JB, White J, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Musall B, Miyoshi M, Wang Z, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Moulder S, Candelaria R, Ma J, Pagel M. Assessment of early response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: pilot study. Virtual - Radiological Society of North America Annual Meeting, 2020.
5. Elshafeey NA, Adrada BE, Kotrotsou A, Abdelhafez AH, Candelaria RP, Yang WT, Sun J, Mohamed R, Boge M, Mahmoud H, Musall B, Son JB, Tripathy D, Santiago L, Thompson A, Valero V, Whitman G, Litton J, Lim B, Le-Petross HC, Leung JT, Lane D, Arribas E, Spak D, Scoggins M, Moseley T, Ueno N, Zhang S, White J, Moulder S, Hwang KP, Wei P, Pagel M, Ma, Rauch GM. Radiomic phenotypes from ultrafast dynamic contrast enhanced (DCE) MRI for prediction of the treatment response to neoadjuvant systemic therapy (NAST) of triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
6. Rauch GM, Adrada BE, Candelaria RP, Elshafeey NA, Mohamed RM, Boge M, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Spak D, Valero V, Litton J, Huo L, Tripathy D, Mittendorf E, Thompson A, Arribas E, Scoggins M, Musall B, Kotrotsou A, Sun J, Son JB, White J, Zhang S, Hwang KP, Wei P, Moulder S, Pagel M, Ma J, Yang WT. Longitudinal MR imaging findings in triple negative breast cancer (TNBC) patients undergoing neoadjuvant systemic therapy (NAST) stratified by tumor infiltrating lymphocytes (TIL) levels. Virtual - Radiological Society of North America Annual Meeting, 2020.
7. Zhang S, Rauch GM, Adrada BE, Abdelhafez AH, Son J, Yang WT, Sun J, Boge M, Mohamed R, Elshafeey N, White J, Musall B, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Candelaria RP, Moulder S, Ma J, Page M. Comparison of chemical exchange saturation transfer (CEST) MRI acquisition and analysis for early neoadjuvant systemic therapy (NAST) treatment response assessment in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
8. Kotrotsou A, Elshafeey NA, Adrada BE, Sun J, Candelaria RP, Abdelhafez AH, Yang WT, Mohamed R, Boge M, Willis B, Musall B, Son JB, Zhang S, Thompson A, Tripathy D, Moseley T, Litton J, Whitman G, Le-Petross HC, Valero V, Santiago L, Lane D, Lim B, Leung JT, Scoggins M, Spak D, Arribas E, White J, Ravenberg E, Cardenas-Rodriguez J, Wei P, Moulder S, Rauch GM, Pagel M. Reliability of pharmacokinetic (PK) parameters by DCE-MRI for prediction of neoadjuvant systemic treatment (NAST) response in triple negative breast cancer (TNBC) patients: a comparison of three analysis methods. Virtual - Radiological Society of North America Annual Meeting, 2020.
9. Guirguis M, Adrada B, Le-Petross HC, Dryden M, Rauch G, Moseley T, Whitman G. Challenging cases in breast localization: a multimodality approach. Virtual - Radiological Society of North America Annual Meeting, 2020.
10. Hwang KP, Vikram R, Ernst R, Rauch G, Devine C, Ma J, Kaur H. Quality improvement and troubleshooting in rectal MRI - how we do it. Virtual - Radiological Society of North America Annual Meeting, 2020.
11. Pagel MD, Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RM, Hamed A, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Wei P, Hwang KP, Ma J. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC). Chemical Exchange Saturation Transfer Imaging 2020 Annual Meeting - Virtual, 2020.
12. Zhang S, Rauch TM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Lane DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Thompson A, Moulder SL, Candelaria RP, Yang W, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: a pilot study. San Antonio Breast Cancer Symposium - Virtual, 2020.
13. Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Holatta M, Rauch GM, Smith BD, Valero V, MacNeill F, Han W, Weber WP, Rauch G, Kuerer H, Heil J. Identify breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment - an international, multicenter analysis. San Antonio Breast Cancer Symposium - Virtual, 2020.
14. Zhang S, Abdelhafez AH, Son JB, Musall BC, Miyoshi M, Wang Z, Hwang KP, Rauch GM, Ma J, Pagel MD. Tumor response to neoadjuvant chemotherapy in triple negative breast cancer using CEST MRI. International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
15. Musall BC, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Pagel MD, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Candelaria RP, Helgason T, Ravenberg EE, Litton JK, Moulder SL, Yang WT, Ma J, Rauch GM, Adrada BE. Diffusion fractional anisotropy in peritumoral edema of triple negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
16. Hwang KP, Wang X, Ernst RD, Palmquist SM, Level M, Rauch GM, Chang GJ, Messick C, Taggart MW, Bayram E, Ma J, Kaur H. Deep learning based image reconstruction for T2-weighted rectal cancer imaging. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
17. Son JB, Hwang KP, Scoggins ME, Basek ED, Rauch GM, Pagel MD, Ma J. Semi-supervised image domain transfer for Dixon water and fat separation. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
18. Zhang S, Abdelhafez AH, Son JB, Musall B, Miyoshi M, Wang X, Hwang KP, Rauch GM, Pagel MD, Ma J. Optimized CEST acquisition and analysis for treatment assessment of response to neoadjuvant chemotherapy in triple-negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
19. Tayyab S, Le-Petross H, Adrada BE, Rauch GM, Moseley T, Sun J, Masood AR. Stromal fibrosis on MRI biopsy: a histopathologic correlation and outcome data. European Congress of Radiology, 2020.
20. Jimenez J, Abeer A, Elshafeey N, Yung J, Hazle J, Rauch G. Quantitative MR imaging features associated with pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. American Association of Physicists in Medicine / Canadian Organization of Medical Physicists Annual Meeting, 2020.
21. Abudadra NK, Lim B, Thompson A, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun BK, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Moulder S, Huo L, White JB, Ravenberg EE, Sun R. The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumor infiltrating lymphocytes (sTIL). Ann Oncol 31(Suppl 2):S49, 2020.
22. Adrada BE, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins ME, Spak DA, Leung JWT, Damodaran S, Lim B, Valero V, White J, Thompson AM, Litton JK, Moulder SL, Ma J, Yang WT, Rauch GM. Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients. Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
23. Abuhadra NK, Lim B, Thompson A, Mittendorf E, Hess KR, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang W, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder S, Huo L. Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). Cancer Res 80(4 Suppl S), 2020.
24. Tasoulis K, Kuerer HM, MacNeill F, Han-Byoel L, Yang W, Pope R, Krishnamurthy S, Teoh V, Rauch GM, Smith B, Valero V. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. Cancer Res 80(4 Suppl), 2020.
25. Seth S, Huo L, Vasaikar S, Rauch G, Lim B, White J, Adrada B, Piwnica-Worms H, Ueno NT, Thompson AM, Mittendorf E, Tripathy D, Litton JK, Symmans WF, Draetta G, Futreal A, Chang J, Moulder S. Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
26. Damodaran S, Litton JK, Hess KR, Eppig CT, Grzegorzewski KJ, Meric-Bernstam F, Wistuba II, White JB, Rauch GM, Candelaria RP, Adrada BE, Lim B, Moulder SL, Tripathy D. A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations. Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
27. Garber H, Rauch G, Adrada B, Candelaria R, Mittendorff E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Tripathy D, Piwnica-Worms H, Symmans F, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). Cancer Res 80(4 Suppl), 2020.
28. Sun S, Van laParra R, Rauch GM, Checka C, Adrosa T, Lucci A, Teshome M, Black S, Hwang R, Smith B, Krishnamurthy S, Velero V, Yang W, Kuerer HM. Patient selection for non-operative management of HER2+ invasive breast cancer after neoadjuvant systemic therapy. Ann Surg Oncol, 2019.
29. Crespo J, Sahil S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada B, Rauch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Characterization of the LAR-subtype triple-negative breast cancer population. Cancer Res 79(13 Suppl):368-369, 2019.
30. Guirguis M, Santiago L, Adrada BE, Rauch GM, Arribas E. Beyond invasive ductal carcinoma: A review of unusual breast malignancies. Proceedings of the American Roentgen Ray Society Annual Meeting, 2019.
31. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria R, Arun B, Yang YT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating (TIL) receiving neoadjuvant therapy. J Clin Oncol 37(15, Suppl), 2019. e-Pub 2019.
32. Tasoulis MK, Lee HB, MacNeill L, Kuerer HM, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. American Society of Clinical Oncology Annual Meeting, 2019.
33. Moulder S, Adrada B, Lim B, Ueno N, Candelaria R, Rauch G, Litton J, Thompson A, Huo L, Hess K. A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST). 16th St. Gallen International Breast Cancer Conference Proceedings 44(Suppl 1):S101 - S102, 2019.
34. Adrada BE, Valero V, Reddy SM, Barcenas CH, Candelaria R, Wei W, Rauch GM. Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC). Cancer Res 79(4 Suppl), 2019.
35. Adrada BE, Candelaria R, Moulder S, Lane D, Santiago L, Arribas E, Hess KR, Valero V, Thompson A, Helgason T, Ravenberg E, Yang W, Rauch GM. Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients. Cancer Res 79(4 Suppl), 2019.
36. Lucci A, Hall C, Hess K, Ravenberg E, Clayborn A, Mittendorf E, Rauch G, Candelaria R, Moulder S, Thompson A. Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Cancer Res 79(4 Suppl), 2019.
37. Seth S, Huo L, Rauch G,R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans WF, Draetta G, Futreal AP, Moulder S, Chang JT. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). Cancer Res 79(4 Suppl), 2019.
38. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. Cancer Res 79(4 Suppl), 2019.
39. Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson A, Mittendorf E, Litton J, Symmans WF, Draetta G, Futreal A, Moulder S, Chang JT. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). J Clin Oncol 37(No. 15 Suppl):586-586, 2019.
40. Musall BC, Adrada BE, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Ma J, Whitman G, Le-Petross H, Moseley T, Candelaria RP, Litton J, Moulder S, Yang WT, Pagel MD, Rauch GM. Optimized tumor volumes by dynamic contrast enhanced MR imaging for assessing response to neoadjuvant chemotherapy in triple negative breast cancer. Proceedings of the 2019 International Society for Magnetic Resonance in Medicine, 2019.
41. Candelaria R, Adrada BE, Santiago L, Lane DL, Wei I, Huang ML, Arribas EM, Rauch GM, Thompson A, Moulder S. Do triple negative breast cancers have characteristic imaging features according to androgen receptor and vimetin status?. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
42. Hall C, Hess K, Ravenberg L, Clayborn A, Rauch G, Candelaria R, Mittendorf EA, Moulder S, Thompson A, Lucci A. Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Ann Oncol 29(Suppl 8), 2018.
43. Yam C, Seth S, Hess K, Mittendorf EA, Murthy R, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang M, Arribas E, Lane D, Rauch G, Adrada B, Gilcrease M, Chang J, Moulder S. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC). Ann Oncol 29(Suppl 8), 2018.
44. Yam C, Hess KR, Litton JK, Yang W, Santiago L, Candelaria RP, Mittendorf E, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology(MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). J Clin Oncol 36(15, Suppl), 2018.
45. Moulder S, Hess K, Candelaria RP, Rauch GM, Santiago L, Adrada BE, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 36(15 Suppl):518-518, 2018.
46. Scoggins M, Santiago L, Arribas E, Rauch G, Lane D, Adrada B. A sheep in wolf's clothing: imaging assessment of multiple intraductal breast papillomas. American Roentgen Ray Society Annual Meeting, 2018.
47. Scoggins M, Rauch G, Candelaria R, Arribas E, Santiago L, Adrada B. Axillary lymphadenopathy on screening mammography: a first sign of hidden danger?. American Roentgen Ray Society Annual Meeting, 2018.
48. Yam C, Fornage BD, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno N, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans F, Moulder SL, Yang W. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer (TNBC). Cancer Res 78(4, Suppl):988, 2018.
49. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf E, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. Cancer Res 78(4, Suppl):618, 2018.
50. Rauch GM, Adrada BE, Kappadath C, Candelaria RP, Huang ML, Santiago L, Moseley T, Scoggins ME, Knudtson JD, Lopez BP, Hess KR, Krishnamurthy S, Moulder S, Valero V, Yang W. Quantitative assessment of tumor response to neoadjuvant chemotherapy in women with locoregional invasive breast cancer using Tc99m sestamibi molecular breast imaging - preliminary results. Cancer Res 78(4, Suppl):795, 2018.
51. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf E, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. Cancer Res 78(4, Suppl):1181, 2018.
52. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Euno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. Cancer Res 78(4, Suppl):136, 2018.
53. Echeverria GV, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch GM, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang JT, Piwnica-Worms H. A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment. J Cancer Res 78(4, Suppl):817, 2018.
54. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Yang WT, Candelaria RP, Leung JW, Elbanan M, Duran AH, Unlu E, Wang M, Moulder S, Wu Y, Mittendorf E, Thompson A. Correlation of MRI texture features with tumor infiltrating lymphocytes and pathologic complete response in HER2 positive and triple negative subtypes of breast cancer. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
55. Rauch GM, Adrada B, Kappadath SC, Lopez B, Hess K, Moseley T, Scoggins M, Candelaria R, Huang M, Knudtson J, Krishnamurthy S, Moulder S, Valero V, Yang W. Prediction of tumor response to neoadjuvant chemotherapy in breast cancer patients using quantitative 99mTc sestamibi Molecular Breast Imaging - Preliminary results. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
56. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci Jr A, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Imaging and imaging-guided biopsy assessment of pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017.
57. Son JB, Rauch GM, Hwang KP, Ma J. An automated single-scan Z-spectrum analysis method for amide proton transfer imaging. 39th Annual International Conference of the IEEE Engineering in Medicine & Biology Society, 2017.
58. Damodaran S, Hess K, Rauch M, Adrada B, Santiago L, Litton J, Mittendorf E, Lim B, Ueno N, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, Moulder SL. NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT). Cancer Res 77(13):Supplement, 2017.
59. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci Jr A, Barcenas CH, Hwang RF, Rauch GM, Santiago L, Strom EA, DeSnyder SM, Yang WT Black DM, Albarracin CT, Mac Gregor MC, Hunt KK, Kuerer HM. Contemporary breast conservation patient outcomes for ductal carcinoma in situ and margins <2mm. J Clin Oncol 35(15, Suppl), 2017.
60. Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 35(15, Suppl), 2017.
61. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients and rationale for elimination of axillary surgery with documented pathologic complete response in the breast after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017.
62. Helgason T, Moulder S, Thompson A, Symmans WF, Hess K, Yang W, Adrada BE, Rauch GM, Gilcrease M, Mittendorf EA, Tripathy D, Ueno NT. NCT02593175: A phase IIB study of neoadjuvant PaCT regimen (panitumumab in combination with carboplatin and paclitaxel) for anthracycline resistant triple-negative breast cancer (TNBC). Cancer Res 77(4, Suppl), 2017.
63. Moulder S, Helgason T, Hess KR, Symmans WF, Adrada BE, Rauch GM, Thompson A, Clayborn AR, Huo L, Gilcrease M, Tripathy D, Mittendorf EA. Triple-negative first-line study: neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489). Cancer Res 77(4, Suppl), 2017.
64. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS S, DeSnyder SM, Santiago L, Lucci A, Hobbs BP, Gilcrease M, Hwang R, Candelaria RP, Chavez Mac-Gregor M, Arribas E, Moseley T, Teshome M, Miggins MV, Smith BD, Valero V, Hunt KK, Yang WT. Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic chemotherapy. Cancer Res 77(4, Suppl), 2017. e-Pub 2016.
65. Echeverria GV, Chang JT, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch GM, Adrada BE, Jennifer L, Moulder SL, Symmans WF, Piwnica-Worms H. An annotated collection of pre- and post-therapy breast cancer patient-derived xenoggraft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment. Cancer Res 77(4), 2017.
66. Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease M, Symmans FW, Huo L, Mittendorf EA, Thompson A, Stacy MTL, Debu T, Ueno NT. Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC). Cancer Res 77(4, Suppl), 2017.
67. Moseley TW, Adrada BE, Rauch GM. Molecular breast imaging. Cancer Study and Therapy Conference, 2017. e-Pub 2017.
68. Arribas E, Huang M, Adrada BE, Rauch GM, Santiago L. The atypical malignant axillary lymph node in breast cancer patients. AJR Am J Roentgenol, 2017.
69. Lopez B, Rauch M, Adrada B, Backe S, Hess K, Kappadath S. Quantification of in Vivo tumor uptake in clinical molecular breast imaging (MBI) examinations. Med Phys 44(6):3263, 2017.
70. Kappadath SC, Lopez B, Adrada B, Hess K, Rauch G. Prediction of breast tumor response to neoadjuvant chemotherapy through quantitative 99mTc sestamibi Molecular Breast Imaging (MBI). Eur J Nucl Med Mol Imaging 44(Suppl 2):5660, 2017.
71. Lopez B, Rauch GM, Adrada BE, Bache S, Hess K, Kappadath SC. Quantifying Tc-99msestamibi uptake in breast tumors using molecular breast imaging. Med Phys 44(6):3263, 2017.
72. Rauch GM, Adrada BE, Kappadath C, Ma J, Muller F, Moulder S, Yang W. In vivo molecular breast imaging with Tc 99m sestamibi for the prediction of multidrug resistance in triple negative breast cancers, 2017.
73. Lane DL, Santiago L, Candelaria RP, Scoggins ME, Rauch GM, Adrada BE, Huang ML, Geiser WR, Hess K. Synthesized mammography (SM) versus full-field digital mammography (FFDM): a comparison of lesion detection by radiologists. Proceedings of the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2016.
74. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of CT- and MRI-based clinical target volume contours at the time of brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 93(3):E282, 2016. e-Pub 2016.
75. Rauch GM, Tamm EP, Bhosale PR, Devine C, Rao-Korivi B, Szklaruk J. Dual energy CT for evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer, 2016.
76. Ho J, Allen P, Bhosale P, Rauch G, Fuller C, Mohamed A, Fruimovitz M, Jhingran A, Eifel P, Klopp A. Functional imaging predictors of outcome in cervical cancer following chemoradiation. Brachytherapy 15(Supplement 1):S106, 2016.
77. Bache S, Adrada B, Jessop A, Rauch G, Kappadath S. Quantification of tumor uptake with molecular breast imaging (MBI). J Nucl Med 57(Suppl):535, 2016.
78. Santiago L, Candelaria RP, Arribas EM, Huang ML, Scoggins ME, Adrada BE, Rauch GM, Thames D, Whitman GJ. Noncalcified ductal carcinoma in situ: the danger that lies beneath. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
79. Rauch GM, Adrada BE, Huang ML, Candelaria RP, Arribas EM, Yang WT, Cox K, Santiago L, Kappadath S. Molecular breast imaging: an adjunct diagnostic modality for breast cancer evaluation. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
80. Candelaria RP, Huang ML, Adrada BE, Arribas EM, Scoggins ME, Yang WT, Schopp J, Dryden M, Le-Petross HC, Moseley T, Whitman G, Rauch GM, Santiago L. Comparing the performance of full-field digital mammography (FFDM), digital breast tomosynthesis (DBT) and whole breast ultrasound (WBUS) in the initial staging evaluation of breast cancer: interim results of a prospective study. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
81. Huang ML, Speer ME, Dogan BE, Rauch GM, Candelaria RP, Yang WT, Hess K, Adrada BE. Following imaging-concordant benign MRI-guided vacuum-assisted breast biopsy: is MRI follow up needed?. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
82. Adrada BE, Huang ML, Candelaria RP, Santiago L, Rauch GM, Arribas EM, Dawson D, Albarracin C, Moseley T, Whitman G. Intraoperative specimen radiography - going beyond the block. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
83. Shin K, Adrada BE, Rauch GM, Benveniste AP, Yang WT. American Joint Committee on Cancer (AJCC) Breast cancer staging - Multimodality regional nodal basin imaging, 2015.
84. Ho J, Allen P, Bhosale P, Rauch G, Fuller C, Mohamed A, Fruimovitz M, Jhingran A, Eifel P, Klopp A. Functional imaging predictors of outcome in cervical cancer following chemoradiation. Int J Radiat Oncol Biol Phys 93(3):E289, 2015.
85. Rauch GM, Tamm E, Bhosale P Devine C, Rao-Korivi B, Szklaruk J. Evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer by dual energy CT imaging. Society of Computed Body Tomography & Magnetic Resonance, 2015.
86. Bache S, Adrada B, Jessop A, Rauch G, Kappadath S. Scatter and attenuation correction approaches for quantitative molecular breast imaging. J Nucl Med 56(3):45, 2015.
87. Arribas EM, Huang ML, Adrada BE, Rauch GM, Gilcrease M, Yang WT. Giant breast masses: differential diagnosis with multimodality and histopathology correlation. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
88. Huang ML, Monetto FP, Arribas EM, Rauch GM, Krishnamurthy S, Adrada BE. Manifestation of hematologic diseases in the breast: multimodality review with patholofic correlation. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
89. Huang ML, Monetto FP, Arribas EM, Rauch GM, Krishnamurthy S, Adrada BE. Primary lymphoma of the breast: multimodality features with pathologic correlation and management review. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
90. Rauch GM, Bhosale PR, Tamm EP, Devine CE, Rao B, Szklaruk J. Hepatobiliary and pancreatic vascular anatomy in the era of dual energy CT (DECT). Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
91. Rauch GM, Hobbs B, Kuerer HM, Scoggins ME, Benveniste AP, Yang WT, Park YM, Adrada BE, Fox P, Krishnamurthy S. Mammographic features of microcalcifications and survival in patients with pure ductal carcinoma in situ of the breast: population based retrospective cohort study. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
92. Swanick CW, Castle KO, Cunningham MG, Vedam S, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Impact of normal tissue motion on dose to critical structures during intracavitary brachytherapy. Radiat Oncol Biol Phys 90(1):S482, 2014.
93. Swanick CW, Castle KO, Rachner LA, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Optimizing packing contrast for MRI-based intracavitary brachytherapy treatment planning. Brachytheraphy 13(Supplement 1):S57-S58, 2014.
94. Adrada BE, Rauch GM, Adeyefa MM, Huo L, Stephens TW, Yang WT. Management of fat necrosis of the breast according to imaging features. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
95. Bathala T, Rauch GM, Bass M, Borst D, Hobbs B, Bedi DG. Diagnostic performance of conventional ultrasonography combined with US strain elastography for differentiation between benign and malignant subcutaneous soft tissue mass lesions. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
96. Rauch GM, Hobbs B, Kuerer H, Scoggins M, Lari S, Yang W, Benveniste AP, Park YM, Adrada B, Fox P, Krishnamurthy S. Microcalcifications in 1,658 patients with pure ductal carcinoma in situ of the breast: imaging findings with clinical, histopathologic and biologic correlation. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
97. Rauch GM, Marcal LP, Castle KO, Klopp A. MRI in intracavitary brachytherapy of the cervical cancer: what radiologists need to know. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
98. Marcal LP, Rauch GM, Kaur H, Foo WC, Loyer EM. Pre-operative imaging of hilar cholangiocarcinoma: what the surgeon wants to know. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
99. Scoggins M, Rauch GM, Fox P, Benvensite AP, Kuerer H, Yang W, Park YM, Lari S, Krishnamurthy S. Sonographic findings in 691 pure ductal carcinoma in situ lesions with histopathologic and biologic correlation. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
100. Rauch GM, Ernst R, Marcal LP, You NY, Chang GJ, Rodriguez-Bigas M, Choi H, Kaur H. High-resolution MRI in the presurgical evaluation of low rectal tumors. American Roentgen Ray Society Annual Meeting, 2013.
101. Rauch GM, Kuerer H, Scoggins M, Benveniste AP, Fox P, Yang W, Park YM, Lari S, Hobbs B, Krishnamurthy S. Biologic subtype and imaging correlates of 1,187 patients with pure ductal carcinoma in situ of the breast. Proceedings of the 98th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2012.
102. Rauch GM, Kuerer HM, Benveniste AP, Scoggins ME, Fox PS, Park YM, Lari SA, Hobbs BP, Krishnamurthy S, Yang W. Ductal carcinoma in situ: correlation of estrogen hormone receptor expression on clinicopathological and imaging features. Proceedings of the 98th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2012.
103. Rauch GM, Marcal LP, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Choi H, Kaur H. High resolution multiplanar MR imaging for pretreatment staging of cervical and endometrial cancer. Society of Computed Body Tomography & Magnetic Resonance, 2012.
104. Rauch GM, Dogan BE, Liu P, Huo L, Yang WT. Underestimation of high-risk lesions at 9-guage MRI-guided vacuum assisted breast biopsies. Proceedings of the Annual Meeting of the American Roentgen Ray Society, 2012.
105. Ernst R, Kaur HN, Rauch GM, Chang G, You Y, Skibber J, Rodriguez-Bigas M, Raval B, Marcal LP, Choi H. Key findings in rectal cancer with emphasis on 3T MRI. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
106. Marcal LP, Rauch GM, Kaur H, Ernst R, Choi H. High-resolution MR imaging of cervical cancer. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
107. Jensen CT, Rauch GM, You YN, Chang GJ, Choi H, Ernst RD, Kaur H. Mucinous adenocarcinoma of the rectum: disease patterns and pitfalls. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
108. Rauch GM, Ernst R, Marcal LP, Boonsirikamchai P, Klopp A, Choi H, Kaur H. Optimization of high-resolution MRI technique for pretreatment staging of cervical and endometrial cancer. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
109. Rauch GM, Ernst R, Marcal LP, You NY, Chang GJ, Skibber J, Rodriguez-Bigas M, Choi H, Kaur H. Role of the high-resolution MRI in the presurgical evaluation of low rectal tumors. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
110. Jensen CT, Ernst R, Chang C, You NY, Hou P, Choi H, Rauch GM, Kaur H. Preoperative MRI staging of rectal cancer. Proceedings of the American Roentgen Ray Society Annual Meeting, 2011.
111. Faria SC, Marcal LP, Bhosale PR, Sagebiel T, Rauch GM, Szklaruk J, Nasseri F, Ginsberg L, Eftekhari F. Large common and uncommon retroperitoneal masses: a radiological approach to the correct diagnosis. Proceedings of the 96th Annual Meeting of the Radiological Society of North America, 2010.
112. Kaur H, Ernst R, Rauch GM, Jensen C, You NY, Hou P, Choi H. Preoperative staging of primary rectal cancer: role of thin section multiplanar 2D T2 imaging, 3D T2 and diffusion-weighted imaging. Proceedings of the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2010.
113. Rauch GM, Dogan B, Liu P, Yang W. Outcome analysis of 9-gauge MRI-guided vacuum assisted breast biopsy. Proceedings of the 95th Annual Meeting of the Radiological Society of North America, 2009.
114. Rauch GM, Vikram R, Vining D, Iyer R. Extracolonic findings on CT colonography in cancer patients. Proceedings of the Annual Meeting of the American Roentgen Ray Society, 2009.
115. Meyer JS, Rauch GM. Before thrombolytic therapy for acute stroke xenon inhalation contrast CT CBF imaging is recommended. Stroke: Abstracts from the 4th World Stroke Congress 31(11):2838, 2000.
116. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for mild cognitive decline and dementia of the vascular and Alzheimer's types. Stroke A Journal of the American Heart Association 31:319, 2000.
117. Meyer JS, Thornby K, Crawford K, Rauch GM, Li Y. Migraine and cluster headaches cause temporary cognitive impairments. Cephalalgia 20:381-382, 2000.
118. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Ann Neurol:41, 2000.
119. Meyer JS, Rauch GM. Cerebral vasodilator responses to Diamox in cortical versus subcortical vascular dementia. Proceedings of the 21st Salzburg Conference, 2000.
120. Meyer JS, Margishvili GM, Haque A, Rauch RA, Terayama Y, Konno S. Risk factors for cerebral degeneration and dementia. Proceedings of the 10th Salzburg Conference:39, 1999.
121. Rauch GM, Meyer JS, Haque A, Rauch RA. Aging: risk factors for cognitive decline and dementia. J Cereb Blood Flow Metab 19(Suppl 1):S15, 1999.
122. Meyer JS, Rauch GM, Mortel KF, Rauch RA, Akiyama H, Konno S, Terayama Y. Risk factors for vascular dementia. J Stroke Cerebrovasc Dis 2(Suppl 1):37-38, 1999.
123. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Mortel KF. Cardiovascular and related risk factors for vascular dementia. Eur Neurol 5(Suppl 1):S4, 1998.
124. Fife C, Meyer JS, Margishvili GM. The use of hyperbaric oxygen in the treatment of headache. Proceedings of the Interdisciplinary Symposium on Hyperbaric Oxygen Therapy (iSHOT 1998):41-53, 1998.
125. Meyer JS, Margishvili GM. Hypertension as a risk factor for vascular dementia. Proceedings of the International Psychogeriatric Association:70, 1998.
126. Konno S, Meyer JS, Margishvili GM, Haque A. Transformed migraine as a cause of chronic daily headache. Proceedings of the XII Migraine Trust International Symposium:14-15, 1998.
127. Meyer JS, Akiyama H, Mortel KF, Konno S, Margishvili GM. Risk factors in cerebral atrophy during human aging. Neurology A(48):206, 1997.
128. Akiyama H, Meyer JS, Mortel KF, Terayama Y, Konno S, Margishvili GM,. Risk factors for cerebral atrophy and cognitive declines. J Cereb Blood Flow Metab 17(Suppl 1):S625, 1997.
129. Meyer JS, Terayama Y, Akiyama H, Konno S, Mortel KF, Margishvili GM, Will PM. Cerebrovascular disease alters the course and symptoms of migraine. J Neurol Sci 150:S35, 1997.
130. Meyer JS, Akiyama H, Terayama Y, Mortel KF, Konno S, Margishvili GM. Cerebral degenerative changes during aging with cognitive declines. J Stroke Cerebrovasc Dis 6:439, 1997.
131. Meyer JS, Terayama Y, Akiyama H, Konno S, Mortel KF, Margishvili GM, Wills PM. Development of cerebrovascular disease alters the course and symptoms of migraine. Headache 37(5):323, 1997.
132. Meyer JS, Terayama Y, Konno S, Akiyama H, Mortel KF, Margishvili GM. Aging and risk factors for cognitive declines. Ann Neurol 42(3):399, 1997.
133. Meyer JS, Terayama Y, Konno S, Akiyama H, Mortel KF, Margishvili GM. Aging: risk factors for cerebral CT changes and risk of dementia. Proceedings of 8th Congress of the International Psychogeriatric Association:81, 1997.
134. Meyer JS, Akiyama H, Terayama Y, Konno S, Mortel KF, Margishvili GM. Classification of the vascular dementias validated. J Stroke Cerebrovasc Dis(6):452, 1997.
135. Margishvili GM, Madorski SV, Duasheva AA, Churilov MV, Lasarev VA. Evaluation of giant basilar aneurysms with transcranial color-coded duplex sonography. Stroke A Journal of the American Heart Association 27(S):794, 1996.
136. Margishvili GM, Amcheslavski VG. TCD evaluation of cerebral blood flow in patients with meningiomas involving the cavernous sinus. Stroke A Journal of the American Heart Association 27(S):795, 1996.
137. Madorski SV, Margishvili GM, Dausheva AA, Churilov MV, Lasarev VA, Fokin MS. Giant basilar aneurysms: use of transcranial color-coded duplex sonography for non-invasive diagnosis and long term follow-up. Proceedings of All-Russian Conference on Modern Methods of Ultrasound Diagnosis:67, 1996.
138. Margishvili GM, Amcheslavski VG, Shimanski VN. Evaluation of blood flow in cerebral basal arteries in patients with craniobasal meningiomas: TCD and AG investigation. Proceedings of All-Russian Conference on Modern Methods of Ultrasound Diagnosis:70, 1996.
139. Margishvili GM, Amcheslavski VG, Madorski SV, Parfenov AL, Toma GI, Fokin MS, Gaitur EI. Non-invasive monitoring in ICU patients after head injury and subarachnoid hemorrhage. Proceedings of 16th Annual Symposium on Computing in Anesthesia and Intensive Care:54, 1996.
140. Amcheslavski VG, Bragina NN, Parfenov AL, Margishvili GM, Toma GI, Gaitur EI, Madorski SV, Shaginian GG. Modern methods of intensive care of head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:18-19, 1996.
141. Amcheslavski VG, Margishvili GM, Parfenov AL, Toma GI, Gaitur EI. Monitoring of severe head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:25-26, 1996.
142. Gaitur EI, Potapov AA, Amcheslavski VG, Lichterman LB, Kravchuk AD, Parfenov AL, Margishvili GM, Toma GI, Emalianov VK, Leonov VG, Fazulin BR. Significance of arterial hypotonia and hypoxia in head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:24-25, 1996.
143. Margishvili GM, Amcheslavski VG, Parfenov AL, Fokin MS, Toma GI, Gaitur EI, Dausheva AA. Complex cerebral monitoring in ICU patients after severe head injury and subarachnoid hemorrhage. Proceedings of All-Russian Congress of Anesthesiology and Reanimathology 1:20, 1996.
144. Amcheslavski VG, Bragina NN, Parfenov AL, Margishvili GM, Toma GI, Gaitur EI, Madorski SV, Shaginian GG. Intensive care for patients in acute period of severe head injury. Proceedings of All-Russian Congress of Anesthesiology and Reanimathology 2:7, 1996.
145. Margishvili GM, Amcheslavski VG, Shimanski VN. TCD Evaluation of cerebral blood flow in patients with tumors involving the cavernous sinus before and after surgery. Cerebrovasc Dis:8, 1996.
146. Amcheslavski VG, Margishvili GM, Madorski SV, Toma GI, Voronina IA. Non-invasive cerebral monitoring in ICU. Proceedings of 4th International Symposium of Central Nervous System Monitoring, 1996.
147. Madorski SV, Amcheslavski VG, Voronina IA, Margishvili GM. Neurophysiological monitoring after hypophysis and hypothalamus tumors excision. Proceedings of 4th International symposium Central Nervous System Monitoring, 1996.
148. Amcheslavski VG, Margishvili GM, Toma GI, Madorski SV, Parfenov AL, Shaginian GG, Gaitur EI. Non-invasive multipurpose cerebral monitoring of head injured patients in ICU. Proceedings of International Conference on Recent Advances in Neurotraumatology:285, 1996.
149. Parfenov AL, Demchuk ML, Amcheslavski VG, Margishvili GM, Shaginian GG, Gaitur EI. Treatment of endogenic intoxication with the use of sodium hypochlorite in resuscitation patients. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:153-154, 1996.
150. Gaitur EI, Potapov AA, Amcheslavski VG, Margishvili GM, Toma GI, Parfenov AL, Emelianov VK, Mukhametdzhavnov HM, Leonov VG, Fazulin BR. Arterial hypotony influence on course and outcomes of severe head injury. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:126-128, 1996.
151. Gaitur EI, Potapov AA, Amcheslavski VG, Margishvili GM, Toma GI, Parfenov AL, Emelianov VK, Mukhametdzhavnov HM, Leonov VG, Fazulin BR. Arterial hypoxemia effect on outcomes in severe isolated and combined cranio-cerebral trauma. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:125-126, 1996.
152. Amcheslavski VG, Madorski SV, Parfenov AL, Margishvili GM, Toma GI, Savin IA, Fokin MS. Peculiarities of critical states in neurosurgical patients in the postoperative period. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:111-112, 1996.
153. Amcheslavski VG, Margishvili GM, Toma GI, Demchuk ML, Dzubanova NA. Nimotop-S in intensive care of critical condition of neurosurgical patients. Proceedings of 3rd Russian Congress Human and Medicine:251, 1996.
154. Amcheslavski VG, Toma GI, Parfenov AL, Margishvili GM, Fokin MS, Gaitur EI. Diagnosis of cerebral hypoxia using near infrared spectroscopy. Proceedings of All-Russian Medical Research Conference:109-110, 1996.
155. Sokolova AA, Margishvili GM, Kopahkov VA, Yundin VI. Use of somatosensory evoked potentials in spinal neurosurgery. J Neurotrauma 12(S):447, 1995.
156. Boldyreva GN, Margishvili GM, Bragina NN. Space occupying lesion influence on limbic system: clinical and neurophysiological analysis. Proceedings of the International Symposium on Structural and Functional Organization of the Brain:25, 1995.
157. Grindle OM, Koptelov YM, Masherov YL, Voronina IA, Margishvili GM. BRAINLOC method for localization of EEG pathological activity zones in patients with space occupying lesions in the brain. Proceedings of the 1st All-Russian Congress in Neurosurgery:191, 1995.
158. Margishvili GM, Bragina NN, Boldyreva GN. Clinical features of mediobasal temporal meningiomas. Proceedings of the 1st All-Russian Congress of Neurosurgery:204, 1995.
159. Amcheslavski VG, Margishvili GM, Dzubanova NA, Madorski SV, Demchuk ML. Nimotop in neurosurgical ICU practice. Proceedings of the 1st All-Russian Congress of Neurosurgery:10, 1995.
160. Boldyreva GN, Manelis NG, Margishvili GM Masherov EL. Influence of limbic system lesions on brain electrical activity. Proceedings of the Symposium on the Neurophysiological Basis for Mental Function Development:11, 1995.
161. Sokolova AA, Margishvili GM, Kopahkov VA, Yundin VI. Value of somatosensory evoked potentials in spinal neurosurgery. Proceedings of the 10th European Congress of Neurosurgery:188, 1995.
162. Bragina NN, Margishvili GM, Amcheslavsi VG, Barkalaya D. The early postoperative period in patients with craniobasal tumors involving the cavernous sinus. Proceedings of the International Skull Base Symposium:36, 1994.
163. Amcheslavsi VG, Bragina NN, Dzubanova N, Barkalaya D, Margishvili GM. The postoperative period in patients with tumors of the skull base region. Proceedings of the International Skull Base Symposium:36, 1994.
164. Margishvili GM, Livshits AV. Somatosensory evoked potentials dynamic in patients after spinal cord tumor surgery. Proceedings of the 1st Congress of Young Clinician Scientists 1:205-206, 1991.
165. Margishvili GM, Duchidze SH. Gnostic disturbances in patients with right hemispheric lesions. Proceedings of the 51st All-Union Students' Scientific Conference:181, 1988.
166. Margishvili GM, Mudchiri T. Leukocytes functional activity in patients with diabetic gangrene. Proceedings of the 50th All-Union Students' Scientific Conference:87, 1987.
167. Margishvili GM, Besselia N. Leukocytes functional activity in pulmonary inflammatory processes. Proceedings of the 49th All-Union Students' Scientific Conference:121, 1986.
168. Margishvili GM. Reaction of different caliber arteries on oliogocytemic hypervolemia. Proceedings of the 48th All-Union Students' Scientific Conference:48, 1985.
169. Litton, JK, Moulder SL, Hess KR, Damodaran S, Rauch GM, Candelaria R, Adrada BE, Symmans F, Murthy RK, Helgason T, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Mittendorf EA. Neoadjuvant trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). Ann Oncol 29(Suppl 8). e-Pub 2018.
170. Seth S, Huo L, Gilcrease M, Lau R, Piwnica-Worms H, Adrada B, Rauch G, Draetta G, Futreal A, Symmans WF, Moulder S, Chang J. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). EJC 103S1:E129. e-Pub 2018.
171. Musall BC, Adrada BE, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Candelaria RP, Litton JK, Moulder SL, Yang WT, Pagel MD, Rauch GM. Quantitative ADC measurement of breast cancer with ssEPI and reduced FOV diffusion weighted imaging techniques. Proceedings of the 2019 International Society for Magnetic Resonance in Medicine. e-Pub 2019.
172. Musall BC, Ma J, Adrada BE, Abdelhafez AH, Candelaria RP, Yang WT, Hess KR, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Leung JWT, Pagel MD, Hwang KP, Bon JB, White JB, Litton JK, Damodaran S, Lim B, Mahmoud HS, Megahed A, Thompson AM, Moulder SL, Rauch GM. Quantitative tumor volumes by fast dynamic contrast enhanced (DCE) MRI predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC). Radiological Society of North America Annual Meeting. e-Pub 2019.
173. Abdelhafez AH, Adrada BE, Musall BC, Ma J, Candelaria RP, Yang WT, Hess KR, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DE, Leung JWT, Pagel MD, Hwang KP, Son JB, White JB, Litton JK, Damodaran S, Lim B, Mahmoud HS, Megahed A, Thompson AM, Moulder SL, Rauch GM. Tumor necrosis at baseline dynamic contrast enhanced (DCE) MRI for prediction of neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC) patients. Radiological Society of North America Annual Meeting. e-Pub 2019.
174. Seth S, Crespo J, Huo L, Thompson A, Mittendorf E, Hess K, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang W, Santiago L, Murthy RK, Sahin A, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. J Clin Oncol 37(15, Suppl):595. e-Pub 2019.
175. Moawad A, Fuentes D, Carter B, Garg N, Rauch GM, Vining D, Elsayes K. Artificial intelligence in diagnostic imaging: current applications and future perspective. Radiological Society of North America Annual Meeting. e-Pub 2019.
176. Kaur H, Chang G, Konishi T, You Y, Rauch GM, Ernst R. Pelvic nodal anatomy and patterns of nodal spread in rectal cancer. Radiological Society of North America Annual Meeting. e-Pub 2019.
177. Guirguis M, Adrada B, Dryden M, Le-Petross HC, Rauch G, Checka C, Whitman G, Moseley T. The feasibility of breast conservation therapy in multifocal/multicentric breast cancer using multiple radioactive seeds: a paradigm shift. Radiological Society of North America Annual Meeting. e-Pub 2019.
178. Candelaria R, Lane D, Santiago L, Huang M, Arribas E, Yang W, Rauch G, Thompson A, Leung J, Moulder S, Adrada B. Predicting pathologic complete response with ultrasound tumor characteristics in triple negative breast cancer patients. Radiological Society of North America Annual Meeting. e-Pub 2019.
179. Adrada B, Candelaria R, Hess K, Moulder S, Santiago L, Arribas E, Moseley T, Lane D, Scoggins M, Litton J, Thompson A, Whitman G, Leung J, Yang W, Rauch G. Precision imaging: early ultrasound evaluation (US) to identify excellent responders to neoadjuvant. Radiological Society of North America Annual Meeting. e-Pub 2019.
180. Rauch GM, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins M, Spak D, Leung JWT, Damodaran S, Lim B, Valero V, White J, Thompson AM, Litton JK, Huo L, Moulder SL, Ma J, Yang WT, Adrada BE. Radiomics of quantitative apparent diffusion coefficient (ADC) from fibroglandular tissue (FGT) for prediction of tumor infiltrating lymphocytes (TIL) levels and neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium. e-Pub 2019.
181. Hwang KP, Banerjee S, Warntjes M, Rauch GM, Ma J, Son JB. 3D multi-parameter mapping of the breast with Dixon fat-water separation. International Society for Magnetic Resonance in Medicine Annual Meeting. e-Pub 2019.
182. Guirguis MS, Adrada BE, Le-Petross H, Dryden MJ, Rauch GM, Whitman GJ, Moseley T. Preoperative bracketing of multifocal breast carcinoma: a multimodality approach. Society of Breast Imaging Symposium.
183. Lim B, Seth S, Huo L, Layman R, Valero V, Thompson A, White J, Litton J, Damodaran S, Candelaria R, Arun B, Rauch G, Murthy R, Zhao L, Zhang J, Ding Q, Symmans WF, Ramirez D, Ibrahim N, Thomas P, Moulder S, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. J Clin Oncol 38(15 Suppl). e-Pub 2020.
184. Abuhadra NK, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf E, Litton E, Damodaran S, Candelaria RP, Arun BK, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Symmans WF, Moulder S, Huo L, White JB, Ravenberg EE. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.
185. Arun B, Zhao L, Bassett RL, Thompson AL, White JB, Layman RM, Barrera Ag, Valero V, Ueno NT, Litton JK, Zhang J, Ravenberg E, Candelaria RP, Rauch GM, Tripathy D, Moulder SL. Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. J Clin Oncol 38(15 Suppl). e-Pub 2020.
186. Yam C, Al-Atrash G, Yen EY, Garber H, Philips AV, Huo L, Yang F, Bassett RL, Sun X, Cuentas RP, Symmans WF, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Mittendorf EA. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.
187. Moulder S, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.

Book Chapters

1. Guo C, Bhosale PR, Rauch GM, Matamoros A, Menias C, Schmeler KM, Venkatesan AM. Tumors of the uterine corpus. In: Oncology: A Multidisciplinary Course, 2019.
2. Haque A, Meyer JS, Rauch GM. Epidemiology of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 1-8, 2001.
3. Meyer JS, Rauch GM. Cardiovascular risk factors contributing to cerebral degenerative changes, cognitive decline, and dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 19-39, 2001.
4. Rauch GM, Meyer JS. Clinical features of patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
5. Haque A, Meyer JS, Rauch GM. Neuropsychological assessments for cognitive decline. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
6. Loeb C, Meyer JS, Rauch GM. Criteria for diagnosis of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
7. Meyer JS, Rauch GM. Classification of subtypes of vascular dementia including subcortical versus cortical dementias. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
8. Meyer JS, Rauch GM, Rauch RA. Neuroimaging in vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
9. Meyer JS, Rauch GM. Prevention and treatment of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
10. Rauch GM, Meyer JS. Estrogen therapy for prevention of dementia in post-menopausal women. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
11. Meyer JS, Rauch GM. Factors influencing long-term survival among patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
12. Meyer JS, Rauch GM, Haque A, Rauch RA. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. In: Vascular Factors in Alzheimer's Disease. Cambridge: UK, 1, 1999.
13. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors contributing to dementias of vascular and Alzheimer types. In: Proceedings of the 1st International Congress on Vascular Dementia: Geneva Switzerland, 67-70, 1999.
14. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors of cerebral hypoperfusion, cognitive decline, and dementia. In: Hemodynamics and cerebral perfusion: new evidence in the pathology of Alzheimer's Disease: Boston, 1999.

Books (edited and written)

1. Meyer JS, Rauch GM, Lechner H, Loeb C, Toole JF. Vascular dementia. Ed(s) Meyer JS, Rauch GM, Lechner H, Loeb C, Toole JF. Futura Publishing Company: Armonk, NY, 2001.

Letters to the Editor

1. Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal selection of breast cancer patients for elimination of surgery following neoadjuvant systemic therapy. Ann Surg 268: e61-e62, 2018.
2. Kuerer HM, Krishnamurthy S, Rauch GM, Smith B, Valero V, Yang W. Response: Vacuum-assisted biopsy to diagnose a pathological complete response in breast cancer patients after neoadjuvant systemic therapy. Ann Surg, 2017.